Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
Comprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/12/3008 |
| _version_ | 1797461384404926464 |
|---|---|
| author | Hironori Arai Yosuke Minami SungGi Chi Yoshikazu Utsu Shinichi Masuda Nobuyuki Aotsuka |
| author_facet | Hironori Arai Yosuke Minami SungGi Chi Yoshikazu Utsu Shinichi Masuda Nobuyuki Aotsuka |
| author_sort | Hironori Arai |
| collection | DOAJ |
| description | Comprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and ovarian cancer, has pioneered a new age marked by the development of new treatments and lifetime management strategies required for patients with potential or presented hereditary cancers. In acute myeloid leukemia (AML), however, few tumor-agnostic or hereditary mutations have been the focus of investigation, with associated molecular-targeted therapies remaining poorly developed. We focused on representative tumor-agnostic mutations such as the <i>TP53</i>, <i>KIT</i>, <i>KRAS</i>, <i>BRCA1</i>, <i>ATM</i>, <i>JAK2</i>, <i>NTRK3</i>, <i>FGFR3</i> and <i>EGFR</i> genes, referring to a CGP study conducted in Japan, and we considered the possibility of developing molecular-targeted therapies for AML with tumor-agnostic mutations. We summarized the frequency, the prognosis, the structure and the function of these mutations as well as the current treatment strategies in solid tumors, revealed the genetical relationships between solid tumors and AML and developed tumor-agnostic molecular-targeted therapies and lifetime management strategies in AML. |
| first_indexed | 2024-03-09T17:18:39Z |
| format | Article |
| id | doaj.art-e166d6bd1b1a46018c29572c12dec3a9 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T17:18:39Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-e166d6bd1b1a46018c29572c12dec3a92023-11-24T13:25:07ZengMDPI AGBiomedicines2227-90592022-11-011012300810.3390/biomedicines10123008Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid LeukemiaHironori Arai0Yosuke Minami1SungGi Chi2Yoshikazu Utsu3Shinichi Masuda4Nobuyuki Aotsuka5Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho 286-0041, JapanDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho 286-0041, JapanDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho 286-0041, JapanDepartment of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho 286-0041, JapanComprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and ovarian cancer, has pioneered a new age marked by the development of new treatments and lifetime management strategies required for patients with potential or presented hereditary cancers. In acute myeloid leukemia (AML), however, few tumor-agnostic or hereditary mutations have been the focus of investigation, with associated molecular-targeted therapies remaining poorly developed. We focused on representative tumor-agnostic mutations such as the <i>TP53</i>, <i>KIT</i>, <i>KRAS</i>, <i>BRCA1</i>, <i>ATM</i>, <i>JAK2</i>, <i>NTRK3</i>, <i>FGFR3</i> and <i>EGFR</i> genes, referring to a CGP study conducted in Japan, and we considered the possibility of developing molecular-targeted therapies for AML with tumor-agnostic mutations. We summarized the frequency, the prognosis, the structure and the function of these mutations as well as the current treatment strategies in solid tumors, revealed the genetical relationships between solid tumors and AML and developed tumor-agnostic molecular-targeted therapies and lifetime management strategies in AML.https://www.mdpi.com/2227-9059/10/12/3008acute myeloid leukemiatumor agnosticsolid tumorgenomic profilinghereditary breast and ovarian cancervariant |
| spellingShingle | Hironori Arai Yosuke Minami SungGi Chi Yoshikazu Utsu Shinichi Masuda Nobuyuki Aotsuka Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia Biomedicines acute myeloid leukemia tumor agnostic solid tumor genomic profiling hereditary breast and ovarian cancer variant |
| title | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia |
| title_full | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia |
| title_fullStr | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia |
| title_full_unstemmed | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia |
| title_short | Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia |
| title_sort | molecular targeted therapy for tumor agnostic mutations in acute myeloid leukemia |
| topic | acute myeloid leukemia tumor agnostic solid tumor genomic profiling hereditary breast and ovarian cancer variant |
| url | https://www.mdpi.com/2227-9059/10/12/3008 |
| work_keys_str_mv | AT hironoriarai moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia AT yosukeminami moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia AT sunggichi moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia AT yoshikazuutsu moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia AT shinichimasuda moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia AT nobuyukiaotsuka moleculartargetedtherapyfortumoragnosticmutationsinacutemyeloidleukemia |